Home » Diamyd, NIDDK Sign Agreement for Diabetes Study
Diamyd, NIDDK Sign Agreement for Diabetes Study
Sweden’s Diamyd Medical has executed a clinical trial agreement with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for a planned clinical study with the Diamyd GAD-alum diabetes vaccine in 126 new onset Type 1 diabetes patients.
The study will be conducted by the NIDDK-sponsored consortium Type 1 Diabetes TrialNet. Under the terms of the agreement, Diamyd Medical will supply clinical-grade material for the trial.
The company plans to begin a Phase III clinical program for treatment of recent-onset Type 1 diabetes patients in the U.S. and Europe. The results from the proposed TrialNet study will complement the findings of these studies, Diamyd said.
Upcoming Events
-
07May
-
14May
-
30May